Qing-Fen Gan currently serves as the Senior Director of Discovery Biology at Bristol Myers Squibb, where she plays a pivotal role in advancing the company’s drug discovery initiatives, particularly within the cardiovascular (CV) and protein homeostasis domains. As the LDO Brisbane Site Lead for the...
Qing-Fen Gan currently serves as the Senior Director of Discovery Biology at Bristol Myers Squibb, where she plays a pivotal role in advancing the company’s drug discovery initiatives, particularly within the cardiovascular (CV) and protein homeostasis domains. As the LDO Brisbane Site Lead for the CV-west disease area, she has recently expanded her responsibilities to encompass the Protein Homeostasis Platform, enhancing the in vitro pharmacology support essential for the development of innovative therapeutics.
With a robust background in in-vitro pharmacology, Qing-Fen has successfully led numerous projects that have culminated in the delivery of multiple clinical candidates. Her expertise lies in developing comprehensive lead discovery strategies and establishing efficient screening funnels that facilitate hit identification and molecular profiling. By leveraging her skills in biochemical and cell-based assay development, she ensures that assays are meticulously designed to meet the specific needs of each project, enabling effective mechanistic binning and data analysis.
Qing-Fen's proficiency in compound clustering and laboratory automation further enhances her ability to streamline workflows and optimize research outcomes. Her adept management of CRO outsourcing not only maximizes resource efficiency but also fosters collaborative partnerships that drive innovation. Additionally, her insights into biomarker discovery and virology contribute to a holistic approach in drug development, ensuring that Bristol Myers Squibb remains at the forefront of therapeutic advancements. Through her leadership and strategic vision, Qing-Fen Gan continues to make significant contributions to the field of drug discovery, ultimately aiming to improve patient outcomes in challenging disease areas.
